Breaking News, Collaborations & Alliances

Aptar Pharma, COVIRIX Medical Partner on Inhaled Antiviral Treatments

If successful, the finished product could potentially be used against numerous pandemic-potential respiratory viruses.

Author Image

By: Patrick Lavery

Content Marketing Editor

Aptar Pharma is starting a technical collaboration with COVIRIX Medical, a feasibility study for a dry powder inhalation (DPI) platform. The DPI platform, proprietary to Aptar Pharma, is being adapted for delivery of COVIRIX Medical’s antiviral compound. If the collaboration is successful, the two parties say they will explore development of an integrated, finished product. This could potentially be used against pandemic-potential respiratory viruses—Covid-19, seasonal and avian influenza, or...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters